Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome

American Journal of Physiology - Renal Physiology

Volumn 280, Issue 5 49-5, 2001, Pages

  Vaziri, N D ^a,c   Liang, K ^a   Parks, J S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arteriosclerosis; High density lipoprotein; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia; Hypoalbuminemia; Proteinuria

Indexed keywords

CHOLESTEROL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PUROMYCIN AMINONUCLEOSIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME DEFICIENCY; HYPOALBUMINEMIA; HYPOLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035026173     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.2001.280.5.f823     Document Type: Article

References (45)

1. Afrasiabi MA, Vaziri ND, Gwinup G, Mays DM, Barton CH, Ness RL, and Valenta LJ. Thyroid function studies in the nephrotic syndrome. Ann Intern Med 90: 335-338, 1979.
2. Agbedana ED, Yamamoto T, Moriwaki Y, Suda M, Takahashi S, and Higashimo K. Studies on abnormal lipid metabolism in experimental nephrotic syndrome. Nephron 64: 256-261, 1993.
3. Akanuma Y, Yokoyama S, Imawari M, and Itakura H. A role of ApoA-1 in LCAT reaction. Scand J Clin Lab Invest Suppl 150: 40-47, 1978.
4. Davies RW, Staprans I, Hutchison FN, and Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 86: 600-605, 1990.
5. de Sain-van der Velden MG, Kaysen GA, Barrett HA, Stel-laard F, Gadellaa MM, Voorbij HA, Reijngoud DJ, and Rabelink TJ. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53: 994-1001, 1998.
6. Elias AN, Carreon G, Vaziri ND, Pandian MR, and Oveisi F. The pituitary-gonadal axis in experimental nephrotic syndrome in male rats. J Lab Clin Med 120: 949-954, 1992.
7. Ettinger WH, Miller LD, Albers JJ, and Parks JS. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomoglus monkeys. J Lipid Res 31: 1099-1107, 1990.
8. Falk RH, Jennette JC, and Nachman PH. Nephrotic syndrome. In: Brenner and Rector's the Kidney, edited by Brenner BM. Philadelphia, PA: Saunders, 2000, p. 1266-1271.
9. Fielding CJ, Shore VG, and Fielding PE. A protein cofactor of lecithin:cholesterol acyltransferase. Biochem Biophys Res Commun 46: 1493-1498, 1972.
10. Francone OL and Fielding CJ. Structure-function relationships in human lecithin:cholesterol acyltransferase. Site-directed mutagenesis at serine residues 181 and 216. Biochemistry 30: 10074-10077, 1991.
11. Francone OL, Gurakar A, and Fielding C. Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem 264: 7066-7072, 1989.
12. Genest J, Jr, Marcil M, Denis M, and Yu L. High density lipoproteins in health and in disease. J Investig Med 47: 31-42, 1999.
13. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9: 155-167, 1968.
14. Huggins KW, Curtiss LK, Gebre AK, and Parks JS. Effect of long chain polyunsaturated fatty acids in the sn-2 position of phosphatidylcholine on the interaction with recombinant high density lipoprotein apolipoprotein A-I. J Lipid Res 39: 2423-2431, 1998.
15. Joles JA, Willekes-Koolschijim N, Scheek LM, Koomans HA, Rabelink TJ, and Van Tol A. Lipoprotein phospholipid composition and LCAT activity in nephrotic and analbuminemic rats. Kidney Int 46: 97-104, 1994.
16. oA reductase inhibitor in heterozygous familial hypercholesterolemia due to 10-Kb deletion ("French Canadian Mutation") of LDL receptor gene. Arterioscler Thromb 14: 1258-1263, 1994.
17. Kaysen GA. The metabolism of serum proteins in nephrosis. Am Kidney Found Nephrol Lett 5: 31-46, 1988.
18. Kaysen GA and de Sain-van der Velden MG. New insights into lipid metabolism in the nephrotic syndrome. Kidney Int Suppl 71: S18-S21, 1999.
19. Khamiseh G, Vaziri ND, Oveisi F, Ahmadnia MR, and Ahmadnia L. Vitamin D absorption, plasma concentration and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med 196: 210-213, 1991.
20. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, and Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 38: 191-205, 1997.
21. Levy E, Ziv E, Bar-On H, and Shafrir E. Experimental nephrotic syndrome: removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin. Biochim Biophys Acta 1043: 259-266, 1990.
22. Liang K and Vaziri ND. Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 130: 387-394, 1997.
23. Liang K and Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 51: 1761-1765, 1997.
24. Liang K and Vaziri ND. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 51: 1933-1937, 1997.
25. Liang K and Vaziri ND. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int 56: 621-626, 1999.
26. Liang KH, Oveisi F, and Vaziri ND. Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 49: 855-860, 1996.
27. Miller KR, Wang J, Sorci-Thomas M, Anderson RA, and Parks JS. Glycosylation structure and enzyme activity of lecithin:cholesterol acyltransferase from human plasma, HepG2 cells, and baculoviral and Chinese hamster ovary cell expression systems. J Lipid Res 37: 551-561, 1996.
28. Nayak SS, Bhaskaranand N, Kamath KS, Baliga M, Venkatesh A, and Aroor AR. Serum apolipoproteins A and B, lecithin: cholesterol acyltransferase activities and urinary cholesterol levels in nephrotic syndrome patients before and during steroid treatment. Nephron 54: 234-239, 1990.
29. Parks JS and Gebre AK. Long-chain polyunsaturated fatty acids in the sn-2 position of phosphatidylcholine decrease the stability of recombinant high density lipoprotein apolipoprotein A-I and the activation energy of the lecithin:cholesterol acyl-transferase reaction. J Lipid Res 38: 266-275, 1997.
30. Russell DW and Setchell KD. Bile acid biosynthesis. Biochemistry 31: 4737-4749, 1992.
31. Sestak TL, Alavi N, and Subbaiah PV. Plasma lipids and acyltransferase activities in experimental nephrotic syndrome. Kidney Int 36: 240-248, 1989.
32. Subbaiah PV and Rodby RA. Abnormal acyltransferase activities and accelerated cholesteryl ester transfer in patients with nephrotic syndrome. Metabolism 43: 1126-1133, 1994.
33. Vaziri ND, Gonzales E, Barton CH, Chen HT, Nguyen Q, and Arquilla M. Factor XIII and its substrates, fibronectin, fibrinogen, and alpha 2-antiplasmin, in plasma and urine of patients with nephrosis. J Lab Clin Med 117: 152-156, 1991.
34. Vaziri ND, Gonzales EC, Shayestehfar B, and Barton CH. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. J Lab Clin Med 124: 118-124, 1994.
35. Vaziri ND, Kaupke CJ, Barton CH, and Gonzales E. Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Am J Med 92: 35-40, 1992.
36. Vaziri ND and Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48: 1979-1985, 1995.
37. Vaziri ND and Liang KH. Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50: 887-893, 1996.
38. Vaziri ND, Liang K, and Park JS. Down regulation of hepatic lecithin: Cholesterol acyltransferase (LCAT) gene expression in chronic renal failure. Kidney Int. In press.
39. Vaziri ND, Ngo JL, Ibsen KH, Mahalwas K, Roy S, and Hung EK. Deficiency and urinary losses of factor XII in adult nephrotic syndrome. Nephron 32: 342-346, 1982.
40. Vaziri ND, Paule P, Toohey J, Hung E, Alikhani S, Darwish R, and Pahl MV. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 144: 1802-1803, 1984.
41. Vaziri ND, Toohey J, Paule P, Hung E, Darwish R, Barton CH, and Alikhani S. Urinary excretion and deficiency of prothrombin in nephrotic syndrome. Am J Med 77: 433-436, 1984.
42. Vlahcevic ZR, Heuman DM, and Hylemon PB. Regulation of bile acid synthesis. Hepatology 13: 590-600, 1991.
43. Wang J, Gehre AK, Anderson RA, and Parks JS. Cloning and in vitro expression of rat lecithin:cholesterol acyltransferase. Biochim Biophys Acta 1346: 207-211, 1997.
44. Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P, and Wieland H. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 119: 263-269, 1993.
45. Zhou XJ and Vaziri ND. Erythropoietin metabolism and pharmacokinetics in experimental nephrosis. Am J Physiol Renal Fluid Electrolyte Physiol 263: F812-F815, 1992.